SUVN G3031

Drug Profile

SUVN G3031

Alternative Names: SUVN-G3031

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class Neuropsychotherapeutics; Nootropics
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders
  • No development reported Parkinson's disease

Most Recent Events

  • 16 Jul 2018 Suven Life Sciences secures product patents for selective 5-HT4 and H3 compounds in Europe and South Korea
  • 17 May 2018 Suven Life Sciences has patent protection for selective H3 inverse agonists and 5-HT6 compounds in Australia and Singapore
  • 16 Nov 2017 Suven Life Sciences has patent protection for selective serotonin (H3 and 5-HT6) compounds for neurodegenerative disorders in USA, Hong Kong and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top